CSTI-100 / HBS-102

About ConSynance Therapeutics

ConSynance Therapeutics, founded in 2021 and based in Cambridge, USA, is a private, clinical-stage biotech focused on rare CNS diseases. Its lead asset, CSTI-500, is a Phase 2-ready, tunable triple monoamine reuptake inhibitor aimed at treating hyperphagia and behavioral dysregulation in Prader-Willi Syndrome. The company is led by a lean, experienced team with deep expertise in CNS drug development, chemistry, and regulatory affairs, positioning it to advance its novel mechanism into critical proof-of-concept studies.

Therapeutic Areas